RT Journal Article
SR Electronic
T1 Cancer cachexia: rationale for the MENAC (Multimodal—Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial
JF BMJ Supportive & Palliative Care
JO BMJ Support Palliat Care
FD British Medical Journal Publishing Group
SP 258
OP 265
DO 10.1136/bmjspcare-2017-001440
VO 8
IS 3
A1 Tora S Solheim
A1 Barry J A Laird
A1 Trude R Balstad
A1 Asta Bye
A1 Guro Stene
A1 Vickie Baracos
A1 Florian Strasser
A1 Gareth Griffiths
A1 Matthew Maddocks
A1 Marie Fallon
A1 Stein Kaasa
A1 Kenneth Fearon
YR 2018
UL http://spcare.bmj.com/content/8/3/258.abstract
AB Cancer cachexia is a multifactorial syndrome characterised by an ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support alone. Cachexia has a high prevalence in cancer and a major impact on patient physical function, morbidity and mortality. Despite the consequences of cachexia, there is no licensed treatment for cachexia and no accepted standard of care. It has been argued that the multifactorial genesis of cachexia lends itself to therapeutic targeting through a multimodal treatment. Following a successful phase II trial, a phase III randomised controlled trial of a multimodal cachexia intervention is under way. Termed the MENAC trial (Multimodal—Exercise, Nutrition and Anti-inflammatory medication for Cachexia), this intervention is based on evidence to date and consists of non-steroidal anti-inflammatory drugs and eicosapentaenoic acid to reduce inflammation, a physical exercise programme using resistance and aerobic training to increase anabolism, as well as dietary counselling and oral nutritional supplements to promote energy and protein balance. Herein we describe the development of this trial.Trial registration number NCT02330926.